COLLEGIUM PHARMACEUTICAL, INC. Series D Convertible Preferred Stock Purchase Agreement Dated as of March 6, 2015

Exhibit 10.30

Execution Version

Series D Convertible Preferred Stock Purchase Agreement

Dated as of March 6, 2015

Table of Contents

		Page

ARTICLE 1 PURCHASE, SALE AND TERMS OF SHARES		1

1.1	Authorization of Series D Convertible Preferred Stock; Definitions	1
1.2	Conversion Shares	1
1.3	The Shares	1
1.4	The Closing	1
1.5	Use of Proceeds	2
1.6	Representations and Warranties by the Purchasers	2

ARTICLE 2 CONDITIONS TO CLOSING		3

2.1	Conditions to Purchaser’s Obligations at the Closing	3
2.2	Conditions to the Company’s Obligations at the Closing	6

ARTICLE 3 REPRESENTATIONS AND WARRANTIES OF THE COMPANY		6

3.1	Organization and Standing; Subsidiaries	7
3.2	Corporate Action	7
3.3	Governmental Approvals	8
3.4	Litigation	8
3.5	Certain Agreements of Officers and Key Employees	9
3.6	Compliance with Other Instruments	10
3.7	Financial Information	10
3.8	No Insolvency	11
3.9	Employee Benefits; ERISA	11
3.10	Transactions with Affiliates	12
3.11	Assumptions or Guaranties of Indebtedness of Other Persons	12
3.12	Investments in Other Persons	12
3.13	Securities Act of 1933	12
3.14	No Disqualification Events	13
3.15	No General Solicitation	13
3.16	Brokers or Finders	13
3.17	Capitalization; Status of Capital Stock	13
3.18	Registration Rights	14
3.19	Insurance	14
3.20	Books and Records	15
3.21	Title to Assets; Patents	15
3.22	Computer Programs	16
3.23	Intellectual Property Rights	16
3.24	Real Property Holding Corporation	16
3.25	Taxes	16
3.26	Other Agreements	16
3.27	OFAC	19
3.28	FCPA	19

3.29	Disclosure	19

ARTICLE 4 DEFINITIONS AND ACCOUNTING TERMS		19

4.1	Certain Defined Terms	19
4.2	Accounting Terms	21

ARTICLE 5 MISCELLANEOUS		21

5.1	No Waiver; Cumulative Remedies	21
5.2	Amendments, Waivers and Consents	21
5.3	Addresses for Notices	21
5.4	Costs, Expenses and Taxes	22
5.5	Binding Effect; Assignment	22
5.6	Prior Agreements	22
5.7	Severability	22
5.8	Governing Law	23
5.9	Headings	23
5.10	Counterparts	23
5.11	Further Assurances	23
5.12	Indemnification	23
5.13	Survival	23
5.14	Delivery by Facsimile or PDF	23
5.15	Delivery by Facsimile or PDF	24
5.16	Acknowledgement	24

SCHEDULES

Schedule A	-	Purchasers
Schedule B	-	Disclosure Schedule

EXHIBITS

1.1		Restated Certificate
2.1(c)(ii)		Opinion of Xxxxxx Xxxxxxxx LLP
2.1(c)(v)		Seventh Amended and Restated Stockholders Agreement
2.1(c)(vii)		Eighth Amended and Restated Investor Rights Agreement

SERIES D CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT

This Series D Convertible Preferred Stock Purchase Agreement (“Agreement”) dated as of March 6, 2015 is entered into by and among Collegium Pharmaceutical, Inc., a Virginia corporation (the “Company”), the individuals and entities listed on Schedule A hereto (each a “Purchaser” and collectively, the “Purchasers”). In consideration of the mutual promises and covenants contained in this Agreement, the parties hereto agree as follows:

ARTICLE 1

PURCHASE, SALE AND TERMS OF SHARES

1.1 Authorization of Series D Convertible Preferred Stock; Definitions. By the filing the Amended and Restated Certificate of Incorporation attached hereto as Exhibit 1.1 (the “Restated Certificate”) with the State Corporation Commission of the Commonwealth of Virginia, the Company has authorized the issuance and sale of up to Forty-One Million Six Hundred Sixty-Six Thousand Six Hundred Sixty Seven (41,666,667) shares (the “Series D Preferred Stock”) of a newly designated Series D Convertible Preferred Stock, par value $0.001 per share (the “Series D Preferred Stock,” together with the Series A Preferred Stock, par value $0.001 per share, the Series B Preferred Stock, par value $0.001 per share and the Series C Preferred Stock, par value $0.001 per share the “Preferred Stock”). The Series D Preferred Stock shall have the rights, privileges, preferences and restrictions set forth in the Restated Certificate. Except as otherwise defined herein, capitalized terms used in this Agreement are defined in Section 4.1.

1.2 Conversion Shares. Prior to the Closing Date (as defined below), the Company has authorized and has reserved and covenants to continue to reserve, free of preemptive rights and other preferential rights, a sufficient number of its previously authorized but unissued shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”), to satisfy the rights of conversion of the holders of the Series D Preferred Stock. Any shares of Common Stock issuable upon conversion of the Series D Preferred Stock are herein referred to as the “Conversion Shares.”

1.3 The Shares. The Series D Preferred Stock issued and sold pursuant to this Agreement are sometimes referred to herein as the “Series D Preferred Shares” and the Series D Preferred Shares and the Conversion Shares are sometimes collectively referred to herein as the “Shares.”

1.4 The Closing. The Company agrees to issue and sell to the Purchasers and, subject to and in reliance upon the representations, warranties, covenants, terms and conditions of this Agreement, including the closing conditions set forth in Section 2.1, the Purchasers, severally but not jointly, agree to purchase that number of Series D Preferred Shares set forth opposite their respective names in Schedule A attached hereto under the heading “No. of Series D Preferred Shares Purchased” at a purchase price of $1.20 per share (“Purchase Price”). The closing of the sale of the Series D Preferred Shares (the “Closing”) shall take place at the offices of Xxxxxx Xxxxxxxx LLP, 000 Xxxx Xxxxxx, Xxxxxx, Xxxxxxxxxxxxx 00000 (or remotely via the exchange of documents and signatures) at 11:00 a.m., Eastern time, on the date of this

Agreement unless another date, place or time is agreed to in writing by the Company and the Purchasers obligated to purchase a majority of the shares of Series D Preferred Shares to be issued pursuant to this Agreement. At the Closing, the Company will issue and deliver certificates evidencing the Series D Preferred Shares to each of the Purchasers against payment of the full purchase price therefor by wire transfer of immediately available U.S. funds or cancellation or conversion of indebtedness.

(a) Conversion of Notes. Each of the undersigned Purchasers holding convertible promissory notes issued by the Company that are to be converted into Series D Preferred Shares as set forth on Schedule A hereto (each a “Note,” and together the “Notes”) hereby acknowledges and agrees that (a) the Company’s sale and issuance of the Series D Preferred Shares to such Purchaser pursuant to this Agreement shall satisfy in full the Company’s obligations with respect to each Note held by such Purchaser and each such Note will automatically be deemed cancelled as of the Closing with no further obligations of the Company thereunder, (b) any interest owed to the Purchasers under the Notes is hereby cancelled, waived and no longer owed by the Company, (c) Schedule A correctly sets forth the principal amount underlying all Note(s) held by such Purchaser and (d) except for principal amount of such Purchaser’s Note(s) as set forth on Schedule A there is no other Indebtedness of the Company owed to such Purchaser. At the Closing, such Purchasers shall surrender to the Company for cancellation such Purchaser’s Note(s) or shall execute an instrument of cancellation in form and substance acceptable to the Company with respect thereto.

1.5 Use of Proceeds. The Company shall use the proceeds only for working capital and operational purposes of the Company, and, except as expressly contemplated by this Agreement, no proceeds will be used in the payment of any debt of the Company, or in the repurchase or cancellation of the Company’s securities without the consent of Purchasers holding a majority of the Shares.

1.6 Representations and Warranties by the Purchasers. Each of the Purchasers represents and warrants severally, but not jointly, to the Company (provided that such representations and warranties do not lessen or obviate the representations and warranties of the Company set forth in this Agreement) that (a) such Purchaser is an “accredited investor” within the meaning of Rule 501 under the Securities Act of 1933, as amended (the “Securities Act”); (b) such Purchaser is acquiring the Shares for such Purchaser’s own account and that the Shares are being and will be acquired by it for the purpose of investment and not with a view to distribution or resale thereof; (c) the execution of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary action on the part of such Purchaser, and this Agreement has been duly executed and delivered, and constitutes a valid, legal, binding and enforceable agreement of such Purchaser; (d) such Purchaser has taken no action which would give rise to any claim by any other person for any brokerage commissions, finders’ fees or the like relating to this Agreement or the transactions contemplated hereby and (e) such Purchaser has sufficient knowledge and experience in finance and business that he, she or it is capable of evaluating the risks and merits of his, her or its investment in the Company and such Purchaser is able financially to bear the risks thereof. Each of the Purchasers further represents and warrants severally, but not jointly, to the Company that, to the extent any Purchaser, or if applicable, any of such Purchaser’s shareholders, members, managers, general or limited partners, directors, affiliates or executive officers, are subject to any of the “Bad Actor”

disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3), the acquisition by each of the Purchasers of the Shares acquired by it will not subject the Company to any Disqualification Event. Furthermore the acquisition by each Purchaser shall constitute a confirmation of the representations and warranties made by each such Purchaser as at the date of such acquisition. Each of the Purchasers further represents that it understands and agrees that, until registered under the Securities Act or transferred pursuant to the provisions of Rule 144 as promulgated by the Securities and Exchange Commission, all certificates evidencing any of the Series D Preferred Stock shall bear a legend, prominently stamped or printed thereon, reading substantially as follows:

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE SOLD, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE ACT, AND APPLICABLE STATE SECURITIES LAWS, OR THE AVAILABILITY OF AN EXEMPTION FROM THE REGISTRATION PROVISIONS OF THE ACT AND APPLICABLE STATE SECURITIES LAWS.”

ARTICLE 2

CONDITIONS TO CLOSING

2.1 Conditions to Purchaser’s Obligations at the Closing. The obligation of each Purchaser to purchase shares of Series D Preferred Shares at the Closing is subject to the fulfillment (or waiver by the Purchasers obligated to purchase a majority of the shares of Series D Preferred Shares to be issued at the Closing), on or before the Closing, of each of the following conditions:

(a) Representations and Warranties. Each of the representations and warranties of the Company set forth in ARTICLE 3 hereof shall be true and correct on the date of the Closing, except for those representations and warranties that address matters only as of a particular date (which shall be true and correct as of such date).

(b) Performance. All covenants, agreements and conditions contained in this Agreement to be performed or complied with by the Company at or prior to the Closing shall have been performed or complied with.

(c) Documentation at Closing. The Purchasers shall have received prior to or at the Closing all of the following documents or instruments, or evidence of completion thereof, each in form and substance satisfactory to the Purchasers and their counsel:

(i) The following documents, each of which shall have been certified by the Secretary of the Company to be true, complete and correct in every particular: (i) a copy

of the Restated Certificate, certified by the State Corporation Commission of the Commonwealth of Virginia as of a recent date, as in effect at the time of Closing; (ii) a resolutions adopted by the Board of Directors evidencing the adoption of the Restated Certificate, the approval of this Agreement, the Financing Documents (as defined below), the issuance of the Series D Preferred Shares and the other matters contemplated hereby; (iii) resolutions adopted by the stockholders of the Company (or a written consent signed by the stockholders of the Company) evidencing the adoption of the Restated Certificate; and (iv) a copy of the Bylaws of the Company.

(ii) An opinion of Xxxxxx Xxxxxxxx LLP, counsel to the Company, in a form set forth in Exhibit 2.1(c)(ii).

(iii) A certificate of the Secretary of the Company certifying the names of the officers of the Company authorized to sign this Agreement, the certificates for the Series D Preferred Shares, and the other documents, instruments or certificates to be delivered pursuant to this Agreement by the Company or any of its officers, together with the true signatures of such officers. The Purchasers may conclusively rely on such certificate until they shall receive a further certificate of the Secretary or an Assistant Secretary of the Company canceling or amending the prior certificate and submitting the signatures of the officers named in such further certificate.

(iv) A certificate of the President of the Company certifying that the conditions specified in Section 2.1(a) and Section 2.1(b) have been fulfilled.

(v) A Seventh Amended and Restated Stockholders Agreement among the Company and the other parties thereto dated of even date herewith and in the form set forth in Exhibit 2.1(c)(v) (the “Stockholders Agreement”) duly executed and delivered by the parties named therein.

(vi) A Certificate of Good Standing for the Company certified by the State Corporation Commission of the Commonwealth of Virginia as of a recent date prior to the Closing date. Certificates of good standing with respect to the Company, certified by the respective state officer of the states in which the conduct of the Company’s business requires it to be licensed or qualified to transact business as a foreign corporation and in good standing, in each case as of a date not more than five (5) Business Days prior to the Closing Date.

(vii) A Eighth Amended and Restated Investor Rights Agreement dated of even date herewith and in the form set forth in Exhibit 2.1(c)(vii) (the “Investor Rights Agreement”) duly executed and delivered by the parties named therein.

(x) Executed proprietary information/assignment of inventions agreements from all current and former Key Employees to the Company.

(d) Board of Directors. The Board of Directors immediately following the Closing shall consist of seven (7) members, of which the members initially shall be Xxxxx Xxxxxx, Xxxx Xxxxxx, Xxxxxxx Xxxxx, Xxxx Xxxxx, Xxxx Xxxxxxx, Xxxxxxx Xxxxxxxxx and Xxxxx Xxxxxx.

(e) Qualifications. As of the Closing, all authorizations, approvals or permits of or filings with, any governmental authority, including state securities or “Blue Sky” offices, that are required by law in connection with the lawful sale and issuance of the Series D Preferred Stock shall have been duly obtained by the Company and shall be effective as of the Closing, except for any notice that may be required subsequent to the Closing under applicable state and/or federal securities laws (which, if required, shall be filed on a timely basis).

(f) Consents, Waivers, Etc. Prior to the Closing, the Company shall have obtained all consents or waivers, if any, necessary to execute and deliver this Agreement and issue the Series D Preferred Stock, and to carry out the transactions contemplated hereby and thereby, and all such consents and waivers shall be in full force and effect. All corporate and other action and governmental filings necessary to effectuate the terms of this Agreement, the Series D Preferred Stock and other agreements and instruments executed and delivered by the Company in connection herewith shall have been made or taken, except for any post-sale filing that may be required under federal or state securities laws. In addition to the documents set forth above, the Company shall have provided to the Purchasers any other information or copies of documents that the Purchasers may reasonably request.

(g) Fees of Purchaser’s Counsel. The Company shall have paid, in accordance with Section 5.4, the fees, expenses and disbursements of Xxxxxx LLP (“Cooley”) and all other counsel to TPG Biotechnology Partners IV, L.P. (“TPG”) invoiced at the Closing.

(h) Corporate Documents. The Company shall have delivered to Purchasers or their counsel copies of all corporate documents of the Company as Purchasers shall reasonably request.

(i) Reservation of Conversion Shares. The Conversion Shares issuable upon conversion of the Series D Preferred Shares shall have been duly authorized and reserved for issuance upon such conversion.

(j) Management Rights. If requested by a Purchaser, a Management Rights letter in a form acceptable to the applicable Purchaser shall have been executed by the Company and delivered to such Purchaser.

(k) Indemnification Agreement. The Company shall have executed and delivered an Indemnification Agreement with Xxxx Xxxxx acceptable to TPG.

(l) Preemptive Rights. The Company shall have fully satisfied (including with respect to rights of timely notification) or obtained enforceable waivers in respect of any rights set forth in the Company’s certificate of incorporation, its bylaws or any contract that directly or indirectly affect the right to purchase any of the Company’s securities from the Company.

(m) Waiver of Interest on Notes. As a condition to the Closing, Purchasers holding Notes shall affirmatively forever cancel and waive any and all interest due and payable under the Notes and shall acknowledge that the interest under the Notes shall not convert into Series D Preferred Shares.

(n) Cancellation of Accrued Dividends. Upon the filing of the Restated Certificate, all accrued but unpaid dividends on the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock shall have been cancelled and extinguished.

(o) Waiver of Anti-Dilution Adjustment. The Company shall have obtained enforceable waivers in respect of any rights to any anti-dilution adjustments or other similar adjustment for the outstanding shares of Preferred Stock in respect of any rights set forth in the Company’s certificate of incorporation, its bylaws or any contract so that the consummation of the transactions contemplated hereunder will not result in any anti-dilution adjustment or other similar adjustment to the outstanding shares of Preferred Stock.

2.2 Conditions to the Company’s Obligations at the Closing. The obligation of the Company to sell Series D Preferred Shares to a Purchaser at the Closing is subject to the fulfillment (or waiver by the Company), on or before the Closing, of each of the following conditions:

(a) such Purchaser shall have paid to the Company the applicable Purchase Price for the Series D Preferred Shares being purchased by such Purchaser at the Closing, by wire transfer of immediately available funds;

(b) the representations and warranties of such Purchaser contained in Section 1.6 shall be true and accurate as of the Closing;

(c) such Purchaser shall have performed and complied with in all material respects all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing;

(d) the Company, the Purchasers and certain of the other stockholders of the Company named as parties thereto shall have executed and delivered the Stockholders Agreement; and

(e) the Company, the Purchasers and certain of the other stockholders of the Company named as parties thereto shall have executed and delivered the Investor Rights Agreement.

ARTICLE 3

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

Except as disclosed by the Company in a written disclosure schedule provided by the Company to the Purchasers dated the date hereof attached hereto as Schedule B (the “Disclosure Schedule”), the Company hereby represents and warrants to each Purchaser that the statements contained in this ARTICLE 3 are complete and accurate as of the date of this Agreement. The Disclosure Schedule shall be arranged in sections corresponding to the numbered and lettered sections and subsections contained in this ARTICLE 3, and the disclosures in any section or subsection of the Disclosure Schedule shall qualify other sections and subsections in this ARTICLE 3 only to the extent it is clear from a reading of the disclosure that such disclosure is applicable to such other sections and subsections.

3.1 Organization and Standing; Subsidiaries.

(a) The Company is a duly organized and validly existing corporation in good standing under the laws of the State of Virginia and has all requisite corporate power and authority for the ownership and operation of its properties and for the carrying on of its business as now conducted and as now proposed to be conducted. The Company is duly qualified and in good standing as a foreign corporation authorized to do business in all jurisdictions wherein the character of the Company’s property owned or leased, or the nature of the activities conducted by the Company, in such jurisdictions makes such qualification necessary, except for such jurisdictions in which the failure to be so qualified would not reasonably be expected to result, individually or in the aggregate, in any material adverse effect on the business, operations, affairs, prospects or condition (financial or otherwise) of the Company or in its properties or assets taken as a whole (a “Material Adverse Effect”).

(b) The Company does not have any Subsidiaries. The Company does not (i) own of record or beneficially, directly or indirectly, (A) any shares of capital stock or securities convertible into capital stock of any other corporation, (B) any participating interest in any partnership, joint venture or other non-corporate business enterprise, or (C) any assets comprising the business or obligations of any other corporation, partnership, joint venture or other non-corporate business enterprise or (ii) control, directly or indirectly, any other entity.

3.2 Corporate Action. The Company has all necessary corporate power and has taken all corporate action required to enter into and perform this Agreement and any other agreements and instruments contemplated hereby or executed in connection herewith, including, without limitation, the Stockholders Agreement and the Investor Rights Agreement (collectively, the “Financing Documents”). The Financing Documents are valid and binding obligations of the Company, enforceable in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors’ rights and general equity principles (whether considered in a proceeding in equity or at law). The issuance, sale and delivery of the Series D Preferred Shares in accordance with this Agreement, and the issuance and delivery of the Conversion Shares upon conversion of the Series D Preferred Shares, have been duly authorized by all necessary corporate action on the part of the Company. Sufficient authorized but unissued shares of Common Stock have been reserved by appropriate corporate action in connection with the prospective conversion of the Series D Preferred Stock and any other Preferred Stock as provided under the Restated Certificate. The Series D Preferred Shares, when issued, sold and delivered in accordance with the terms of this Agreement, and the Conversion Shares when issued upon conversion of the Series D Preferred Shares, will be duly and validly issued, fully paid, non-assessable and neither the Series D Preferred Shares, nor the Conversion Shares when issued upon the conversion of the Series D Preferred Shares, will be, subject to preemptive rights or other preferential rights in any present stockholders of the Company, will not be subject to any Lien, and will not conflict with any provision of any agreement or instrument to which the Company is a party or by which it or its property is bound nor be subject to any restrictions on transfer other than restrictions imposed or created under the Financing Documents, by applicable law, or by the Purchaser.

3.3 Governmental Approvals; Regulatory.

(a) Subject to the accuracy of the representations of the Purchasers in Section 1.6, except for the filing of any notice subsequent to Closing that may be required under applicable state and/or federal securities laws (which, if required, shall be filed on a timely basis), no authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, is or will be necessary for the execution and delivery by the Company of this Agreement, for the offer, issue, sale and delivery of the Series D Preferred Shares, for the issue and delivery of the Conversion Shares upon conversion of the Series D Preferred Shares, or for the performance by the Company of its obligations under this Agreement.

(a) The Company has all franchises, permits, licenses and any similar authority reasonably necessary for the conduct of its business as now being conducted, including without limitation, the Food and Drug Administration (the “FDA”) of the U.S. Department of Health and Human Services. The feasibility, nonclinical and other studies and tests conducted by or on behalf of or sponsored by the Company or in which the Company or the Company’s products under development have participated, if any, were and, if still pending, are being conducted in accordance with standard scientific research procedures. The Company has operated and currently is in compliance in all material respects with all applicable laws in connection with all feasibility and nonclinical and clinical studies, including, as applicable any FDA or foreign equivalent rules and regulations. The Company has not received any notices or other correspondence from the FDA or any other governmental agency or third party requiring the termination, suspension or modification of any of the above referenced feasibility, nonclinical or clinical studies or tests or alleging a violation of any applicable laws or regulations in connection with any nonclinical or clinical studies. Neither the Company nor its agents or affiliates have received any notice that any governmental authority (including the FDA) has commenced or, to the Company’s knowledge, threatened to initiate any action to withdraw to hinder approval for a product or to limit the ability of the Company to manufacture (or to have manufactured for it by a third party) any product or to request the recall of any product, or commenced or threatened to initiate any action to enjoin production of such product at any facility.

3.4 Litigation. Except as set forth in Section 3.4 of the Disclosure Schedule, there is no litigation or governmental proceeding or investigation pending or, to the Company’s knowledge, threatened against the Company affecting any of the Company’s properties or assets, or against any officer, Key Employee or holder of more than 5% of the capital stock of the Company (other than any Purchaser) relating to such person’s performance of duties for the Company or relating to such Person’s stock ownership in the Company or otherwise relating to the business of the Company, nor, to the knowledge of the Company has there occurred any event or does there exist any condition on the basis of which any such litigation, proceeding or investigation might be properly instituted. Neither the Company nor, to the Company’s knowledge, any officer, Key Employee or holder of more than 5% of the capital stock of the Company (other than any Purchaser) is in default with respect to any order, writ, injunction, decree, ruling or decision of any court, commission, board or other governmental agency affecting the Company or any of its assets or properties. There are no actions, suits, claims, investigations or proceedings pending or, to the knowledge of the Company, threatened (or any basis therefor) which could reasonably be expected to result in a Material Adverse Effect. The foregoing sentences include, without limiting their generality, actions pending or, to the

knowledge of the Company, threatened against the Company involving the prior employment of any of the Company’s officers or employees or their use in connection with the Company’s business of any information or techniques allegedly proprietary to any of their former employers. There is no action, suit, proceeding or investigation by the Company currently pending or which the Company intends to initiate.

3.5 Certain Agreements of Officers and Key Employees.

(a) Except as listed in Section 3.5(a) of the Disclosure Schedule, the Company is not a party to nor obligated in connection with its business with respect to (i) outstanding contracts with employees, agents, consultants, advisers, sales representatives, distributors, sales agents or dealers or (ii) collective bargaining agreements or contracts with any labor union or other representative of employees or any employee benefits provided for by any such agreement. To the knowledge of the Company, no officer or Key Employee of the Company is in violation of any term of any employment contract, patent disclosure agreement, proprietary information agreement, non-competition agreement, or any other contract or agreement or any restrictive covenant relating to the right of any such officer or Key Employee to be employed by the Company because of the nature of the business conducted or to be conducted by the Company or relating to the use of trade secrets or proprietary information of others, and, to the knowledge of the Company, the continued employment of the Company’s officers and Key Employees does not subject to the Company or any Purchaser to any liability to third parties. Each current and former employee, consultant and officer of the Company, who either alone or in concert with others develops, invents, programs or designs any Intellectual Property Rights of the Company, has executed an agreement with the Company regarding confidentiality and proprietary information substantially in the form or forms delivered to the counsel for the Purchasers (the “Confidential Information Agreements”). No current or former Key Employee has excluded works or inventions from his or her assignment of inventions pursuant to such Key Employee’s Confidential Information Agreement. The Company does not believe it is or will be necessary to use any inventions of any of its employees or its Subsidiaries’ employees (or persons it currently intends to hire) made prior to their employment by the Company.

(b) To the extent that any current or former employee, consultant and officer of the Company has not signed a Confidential Information Agreement, none of such employees, consultants or officers were involved with the development, inventing, programing or design of DETERx or any other Intellectual Property Rights of the Company. To the extent that any current or former employee, consultant and officer of the Company has signed a Confidential Information Agreement after the commencement of their employment or service relationship with the Company, none of such employees, consultants or officers were involved with the development, inventing, programing or design of DETERx or any other Intellectual Property Rights of the Company.

(c) To the knowledge of the Company, no officer of the Company nor any Key Employee of the Company has expressed any present intention of terminating his employment with the Company. The Company has no present intention of terminating any officer or Key Employee of the Company.

3.6 Compliance with Other Instruments. The Company is not in violation or default under the terms and provisions of this Agreement, of its certificate of incorporation and bylaws, and of all mortgages, indentures, leases, material agreements and other instruments, if any, by which it is bound or to which it or any of its respective properties or assets are subject. The Company is not in default under any judgments, decrees or governmental orders, or material statutes, rules or regulations by which it is bound or to which any of its properties or assets are subject. Neither the execution and delivery of this Agreement or the issuance of the Shares, nor the consummation of any transaction contemplated by this Agreement, has constituted or resulted in or will constitute or result in a material default or violation of any term or provision of any of the foregoing documents, instruments, judgments, agreements, decrees, orders, statutes, rules and regulations, or result in the creation of any mortgage, pledge, lien, encumbrance or charge upon any of the properties or assets of the Company or the suspension, revocation, impairment, forfeiture or nonrenewal of any permit, license, authorization or approval applicable to the Company, its business or operations or any of its assets or properties.

3.7 Financial Information. The (i) audited balance sheet of the Company at December 31, 2013 and the related statements of operations and cash flows for the fiscal year then ended and (ii) the audited balance sheet of the Company at December 31, 2014 and the related statements of operations and cash flows for the fiscal year then ended, attached hereto as Section 3.7 of the Disclosure Schedule (collectively, the “Financial Statements”), present fairly in all material respects the financial position of the Company as of the dates thereof and the results of operations for the period covered thereby (subject, in the case of such unaudited financial statements, to immaterial year-end audit adjustments) and have been prepared in accordance with generally accepted accounting principles (“GAAP”) consistently applied, except for the absence of footnotes not customarily included in such statements. The Company does not have, and the Company does not have reasonable grounds to know of, any liability, contingent or otherwise, over $50,000 not adequately reflected in or reserved against in the aforesaid December 31, 2014 balance sheet, other than liabilities arising in the ordinary course of business since on or after December 31, 2014. There are no accrued (or other declared but unpaid) dividends as of the Closing.

Except as set forth in Section 3.7 of the Disclosure Schedule, since December 31, 2014, there has been no:

(a) change in the assets, liabilities, financial condition or operating results of the Company from that reflected in the Financial Statements, except changes in the ordinary course of business that have not caused, in the aggregate, a Material Adverse Effect;

(b) any damage, destruction or loss, whether or not covered by insurance, that would have a Material Adverse Effect;

(d) any satisfaction or discharge of any lien, claim, or encumbrance or payment of any obligation by the Company, except in the ordinary course of business and the satisfaction or discharge of which would not have a Material Adverse Effect;

(e) any material change to a material contract or agreement by which the Company or any of its assets is bound or subject;

(f) any material change in any compensation arrangement or agreement with any employee, officer, director or stockholder;

(g) any resignation or termination of employment of any officer or Key Employee of the Company;

(h) any mortgage, pledge, transfer of a security interest in, or lien, created by the Company, with respect to any of its material properties or assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and do not materially impair the Company’s ownership or use of such property or assets;

(i) any loans or guarantees made by the Company to or for the benefit of its employees, officers or directors, or any members of their immediate families, other than travel advances and other advances made in the ordinary course of its business;

(j) any declaration, setting aside or payment or other distribution in respect of any of the Company’s capital stock, or any direct or indirect redemption, purchase, or other acquisition of any of such stock by the Company;

(k) any sale, assignment or transfer of any Intellectual Property Rights;

(l) to the Company’s knowledge, any other event or condition of any character, other than events affecting the economy or the Company’s industry generally, that could reasonably be expected to result in a Material Adverse Effect; or

(m) any arrangement or commitment by the Company to do any of the things described in this Subsection 3.7.

3.8 No Insolvency. No insolvency proceeding of any character, including, without limitation, bankruptcy, receivership, reorganization, composition or arrangement with creditors, voluntary or involuntary, affecting the Company or any of its assets or properties, is pending or, to the knowledge of the Company, threatened. The Company has not taken any action in contemplation of, or that would constitute the basis for, the institution of any such insolvency proceedings.

3.9 Employee Benefits; ERISA. The Company has complied in all material respects with all applicable laws relating to wages, hours and collective bargaining. Except as set forth on Section 3.9 of the Disclosure Schedule, the Company has not maintained, sponsored, adopted, made contributions to or obligated itself to make contributions to or to pay any benefits or grant rights under or with respect to any “Employee Pension Benefit Plan” as defined in Section 3(2) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), “Employee Welfare Benefit Plan” (as defined in Section 3(1) of ERISA), “multi-employer plan” (as defined in Section 3(37) of ERISA), plan of deferred compensation, medical plan, life insurance plan, long-term disability plan, dental plan or other plan providing for the welfare of any of the Company’s or any Affiliate’s employees or former employees or beneficiaries thereof, personnel

policy, excess benefit plan, bonus or incentive plan (including but not limited to stock options, restricted stock, stock bonus and deferred bonus plans), salary reduction agreement, change-of-control agreement, consulting agreement, worker’s compensation law, unemployment compensation law, social security law or any other benefit program or contract, except as required by law. Each of such employee benefit plans and programs listed on Section 3.9 of the Disclosure Schedule complies in all material respects with (a) all applicable requirements of ERISA, and (b) all applicable requirements of the Code.

3.10 Transactions with Affiliates. Except as set forth on Section 3.10 of the Disclosure Schedule and except as contemplated hereby or consented to by the Purchasers in accordance with this Agreement, there are no loans, leases, royalty agreements or other continuing transactions between the Company and (a) any officer, employee or director of the Company, (b) any member of the immediate family of such officer, employee, director or stockholder, or (c) any corporation or other entity controlled by such officer, employee, director or stockholder or a member of the immediate family of such officer, employee, director or stockholder. None of the officers, directors or, to the best of the Company’s knowledge, Key Employees or stockholders of the Company or any members of their immediate families, is indebted to the Company or has any direct or indirect ownership interest in any firm or corporation with which the Company is affiliated or with which the Company has a business relationship, or any firm or corporation that competes with the Company, other than (i) passive investments in publicly traded companies (representing less than 1% of such company) which may compete with the Company and (ii) investments by venture capital funds with which directors of the Company may be affiliated and service as a board member of a company in connection therewith due to a person’s affiliation with a venture capital fund or similar institutional investor in such company. No officer, director or stockholder, or any member of their immediate families, is, directly or indirectly, interested in any material contract with the Company (other than such contracts as relate to any such person’s ownership of capital stock or other securities of the Company).

3.11 Assumptions or Guaranties of Indebtedness of Other Persons. Except as set forth on Section 3.11 of the Disclosure Schedule, the Company has not assumed, guaranteed, endorsed or otherwise become directly or contingently liable on (including, without limitation, liability by way of agreement, contingent or otherwise, to purchase, to provide funds for payment, to supply funds to or otherwise invest in the debtor or otherwise to assure the creditor against loss), any Indebtedness of any other Person.

3.12 Investments in Other Persons. The Company has not made any loan or advance to any Person, other than in the normal course of business and on an arm’s length basis on commercially reasonable terms and as reflected in the Financial Statements, which, after giving effect to the transactions contemplated hereby, is outstanding on the date of this Agreement, nor is it committed or obligated to make any such loan or advance.

3.13 Securities Act of 1933. Assuming the representations of the Purchasers in Section 1.6 are true and correct, the offer, issuance and sale by the Company to the Purchasers of the Shares are, and will be as of each Closing, exempt from the registration and prospectus delivery requirements of the Securities Act, and have been, or will be as of each Closing, registered or qualified (or are, or will be as of each Closing, exempt from registration and qualification, subject to the completion of any post-sale Blue Sky filings, which filings the Company agrees it

will complete) under the registration, permit or qualification requirements of the applicable state Blue Sky laws.

3.14 No Disqualification Events. None of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the offering, any beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, a “Company Covered Person” and, together, “Company Covered Persons”) is subject to any Disqualification Event, except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Company Covered Person is subject to a Disqualification Event.

3.15 No General Solicitation. In connection with the offering of Shares made pursuant to this Agreement, the Company has not published, distributed, issued, posted or otherwise used or employed and shall not publish, distribute, issue, post or otherwise use or employ any form of general solicitation or general advertising within the meaning of Rule 502 under the Securities Act.

3.16 Brokers or Finders. No Person has or will have, as a result of the transactions contemplated by this Agreement, any right, interest or valid claim against or upon the Company for any commission, fee or other compensation as a finder or broker because of any act or omission by the Company or any of their respective agents.

3.17 Capitalization; Status of Capital Stock. Upon the filing of the Restated Certificate with the State Corporation Commission of the Commonwealth Virginia, the Company will have a total authorized capitalization, immediately prior to Closing, consisting of (a) One Hundred Thirteen Million (113,000,000) shares of Common Stock, Six Million Nine Hundred Forty-Seven Thousand Eight Hundred Thirty-Seven (6,947,837) of which shares are issued and outstanding on the date hereof; and (b) Eight-Six Million Eight Hundred Ninety-Eight Thousand One Hundred Eighteen (86,898,118) shares of Preferred Stock, of which (i) Nine Million Two Hundred Forty-Nine Thousand Two Hundred Six (9,249,206) shares have been designated as Series A Preferred Stock, and of which Nine Million Two Hundred Thirty-Two Thousand Three Hundred Thirty-Four (9,232,334) shares are issued and outstanding on the date hereof, (ii) Twenty-Seven Million Two Hundred Twenty-Four Thousand Two Hundred Thirty Seven (27,324,237) shares have been designated as Series B Preferred Stock, and all of which are issued and outstanding on the date hereof, (iii) Eight Million Six Hundred Fifty-Eight Thousand Eight (8,658,008) shares have been designated as Series C Preferred Stock, and all of which are issued and outstanding on the date hereof, and (iv) Forty-One Million Six Hundred Sixty-Six Thousand Six Hundred Sixty-Seven (41,666,667) shares have been designated as Series D Preferred Stock, none of which are issued and outstanding on the date hereof, without giving effect to the transactions contemplated hereby. A complete list of the capital stock of the Company outstanding and registered on the stock transfer books of the Company immediately after the Closing is set forth in Section 3.17 of the Disclosure Schedule (such list of capital stock to include a statement of outstanding shares of Common Stock on as converted basis). All of the outstanding shares of capital stock of the Company have been duly authorized, and are validly issued, fully paid and non-assessable. The Series D Preferred Shares, when issued and delivered

in accordance with the terms hereof and after payment of the purchase price therefor, and the Conversion Shares, when issued and delivered upon conversion of the Series D Preferred Shares in accordance with the terms of the Restated Certificate, as amended from time to time, will be duly authorized, validly issued, fully-paid and non-assessable. Except as otherwise set forth in the Investor Rights Agreement and on Section 3.17 of the Disclosure Schedule, no preemptive, conversion or other rights, options, warrants, subscriptions or purchase rights of any nature to acquire from the Company shares of capital stock or other securities are authorized, issued or outstanding, nor is the Company obligated in any other manner to issue shares of its capital stock or other securities except as contemplated by this Agreement. Each outstanding series of Preferred Stock is convertible into Common Stock on a one-for-one basis as of the date hereof and the consummation of the transactions contemplated hereunder will not result in any anti-dilution adjustment or other similar adjustment to the outstanding shares of Preferred Stock. In addition to the complete list of the capital stock of the Company outstanding and registered on the stock transfer books of the Company, Section 3.17 of the Disclosure Schedule sets forth (i) with respect to restricted Common Stock, vesting schedule and repurchase price; (ii) granted stock options, including vesting schedule and exercise price; and (iii) warrants or stock purchase rights (other than the stock purchase rights set forth in the Investor Rights Agreement), if any. Except as set forth in Section 3.17 of the Disclosure Schedule, there are no restrictions on the transfer of shares of capital stock of the Company other than those imposed by the Financing Documents, by applicable law or by the Purchaser. Other than as provided in the Financing Documents, to the knowledge of the Company there are no agreements, understandings, trusts or other collaborative arrangements or understandings concerning the voting of the capital stock of the Company. The offer and sale of all capital stock and other securities of the Company issued before the Closings has not violated the Securities Act, or any state securities laws and no stockholder has a right of rescission with respect thereto. There are no accrued dividends payable to any shares of the Company’s capital stock. The Company has authorized and reserved 11,115,000 shares of Common Stock solely to be used to pay the Series D Accruing Dividends upon conversion of the Series D Preferred Stock, if so elected by the holders of Series D Preferred Stock.

Under the Company’s 2014 Stock Incentive Plan, as amended (the “Plan”), (i) no shares have been issued pursuant to restricted stock purchase agreements, (ii) 219,414 have been issued pursuant to the exercise of outstanding options and are reflected as outstanding in the foregoing paragraph, (iii) options to purchase 1,934,718 shares have been granted and are currently outstanding, and (iv) 5,346,204 shares of Common Stock remain available for future issuance to officers, directors, employees and consultants of the Company.

3.18 Registration Rights and Voting Rights. Except for the rights granted to the Purchasers pursuant to the Investor Rights Agreement, no Person has demand or other rights to cause the Company to file any registration statement under the Securities Act relating to any securities of the Company or any right to participate in any such registration statement. To the Company’s knowledge, except as contemplated in the Stockholders Agreement, no stockholder of the Company has entered into any agreement with respect to the voting of equity securities of the Company.

3.19 Insurance. The Company carries insurance covering its properties and businesses customary for the type and scope of its properties and businesses.

3.20 Books and Records. The books of account, ledgers, order books, records and documents of the Company accurately and completely reflect all material information relating to the business of the Company, the location and collection of its assets, and the nature of all transactions giving rise to the obligations or accounts receivable of the Company.

3.21 Title to Assets; Patents.

(a) Other than (i) any lien in respect of current taxes not yet due and payable, and (ii) liens and encumbrances which do not in any case individually or in the aggregate materially detract from the value of the property subject thereto or materially impair the operations of the Company, and which have arisen in the ordinary course of business and shall be removed within a reasonable period, the Company has good and marketable title in fee to such of its fixed assets, if any, as are real property, and good and marketable title to all of its other assets and properties, free of any Liens of any kind, except for those disclosed on Section 3.21 of the Disclosure Schedule. The Company enjoys peaceful and undisturbed possession under all leases under which it is operating, and all said leases are valid and subsisting and in full force and effect. All facilities, machinery, equipment, fixtures, vehicles and other properties owned, leased or used by the Company are in good operating condition and repair and are reasonably fit and usable for the purposes for which they are being used.

(b) Set forth in Section 3.21 of the Disclosure Schedule is a list of all patents, patent applications, trademarks, trademark applications, service marks, service xxxx applications, trade names and registered copyrights, and applications for such that are in the process of being prepared, owned by or registered in the name of the Company, or of which the Company is a licensor or licensee or in which the Company has any right. Except as set forth in Section 3.21 of the Disclosure Schedule, there is no adverse claim to the Company’s knowledge that would interfere with the Company’s right to use the patents, patent rights, permits, licenses, trade secrets, trademarks, trademark rights, trade names or trade name rights or franchises, copyrights, inventions, software and intellectual property rights being used in the Company’s business as now operated and as now proposed to be operated; to the Company’s knowledge, the conduct of the Company’s business as now operated and as now proposed to be operated does not conflict and will not conflict with valid patents, patent rights, permits, licenses, trade secrets, trademarks, trademark rights, trade names or trade name rights or franchises, copyrights, inventions, and intellectual property rights of any other Person. To the Company’s knowledge no product or process presently used or proposed to be manufactured, marketed, offered, sold or used by the Company will violate any license or infringe on any Intellectual Property Rights of any other Person; and, except as set forth in Section 3.21 of the Disclosure Schedule, the Company has neither received notice that the Company’s Intellectual Property Rights conflict with the rights of others, nor would the present operation or proposed operation of the Company’s business conflict with the rights of others. Except as set forth in Section 3.21 of the Disclosure Schedule, no claim is pending or, to the Company’s knowledge, threatened to the effect that any such Intellectual Property Rights owned or licensed by the Company, or which the Company otherwise has the right to use, is invalid or unenforceable by the Company, and the Company has no reason to believe that any patents or Intellectual Property Rights owned or used by the Company may be invalid. Except as set forth in Section 3.21 of the Disclosure Schedule, the Company has no obligation to compensate any Person for the use of any such patents or rights and the Company has not granted any Person any license or other rights to use in any

manner any of the patents or rights of the Company, whether requiring the payment of royalties or not. Except as set forth on Section 3.21 of the Disclosure Schedule, the Company has not entered into any agreement to indemnify any other Person against any charge of infringement of any patent, trademark, trade name, service xxxx or copyright.

3.22 Computer Programs. Set forth in Section 3.22 of the Disclosure Schedule is a list of the Computer Programs owned, licensed or otherwise used by the Company (excluding off-the-shelf software programs licensed by the Company pursuant to “shrink wrap” or “click through” licenses) in connection with the operation of its business as currently conducted or proposed to be conducted identifying with respect to each such Computer Program whether it is owned, licensed or otherwise used by the Company. The Company does not own, license or otherwise use any Computer Programs (other than off-the-shelf computer programs) that is material to the conduct of its business as currently conducted or proposed to be conducted.

3.23 Intellectual Property Rights. The Company owns or possesses or otherwise has the legally enforceable right to use, and has the right to bring actions for infringement of all Intellectual Property Rights necessary for the conduct of its business as currently conducted or, to the knowledge of the Company, as now proposed to be conducted.

3.24 Real Property Holding Corporation. Since its date of incorporation, the Company has not been, and as of the date of Closing shall not be, a “United States real property holding corporation,” as defined in Section 897(c)(2) of the Internal Revenue Code of 1986 (the “Code”), and in Section 1.897-2(b) of the Treasury Regulations issued thereunder. The Company has no current plans or intentions which would cause the Company to become a “United States real property holding corporation,” and the Company has filed with the IRS all statements, if any, with its United States income tax returns which are required under Section 1.897-2(h) of the Treasury Regulations.

3.25 Taxes. Except as set forth in Section 3.25 of the Disclosure Schedule, the Company has filed all tax returns, federal, state, county and local, domestic and foreign, required to be filed by it, and the Company has paid all taxes shown to be due by such returns as well as all other taxes, assessments and governmental charges which have become due or payable, including without limitation all taxes which the Company is obligated to withhold from amounts owing to employees, creditors and third parties, except to the extent being contested in good faith. The Company has established adequate reserves for all taxes accrued but not yet payable to the extent required by generally accepted accounting principles. Except as set forth in Section 3.25 of the Disclosure Schedule, all material tax elections of any type which the Company has made as of the date hereof are set forth in the financial statements referred to in Section 3.7. No deficiency assessment with respect to or, proposed adjustment of the Company’s federal, state, county or local taxes, domestic and foreign, is pending or, to the knowledge of the Company, threatened. There is no tax lien (other than for current taxes not yet due and payable), whether imposed by any federal, state, county or local taxing authority, domestic or foreign, outstanding against the assets, properties or business of the Company.

3.26 Other Agreements. Except as set forth in the Financing Documents or as set forth in Section 3.26 of the Disclosure Schedule, the Company is not a party to or otherwise bound by any written:

(a) pension, profit sharing, retirement, bonus, incentive, stock option, phantom stock, employee stock purchase or other plan or arrangement providing for deferred or other compensation to employees or any other employee benefit plan, arrangement or practice, whether formal or informal;

(b) collective bargaining agreement or any other contract with any labor union, or severance agreements, programs, policies or arrangements;

(c) contract for the employment (other than employee offer letters provided in the ordinary course of business to employees other than officers) of any officer, individual employee or other Person on a full-time, part-time, consulting or other basis or any agreement providing for the payment of any cash or other compensation or benefits upon the consummation of the transactions contemplated hereby or any agreement relating to a loan to any officers, directors or Affiliates;

(d) agreement or arrangement requiring the consent of any party thereto or containing any provision which would result in an acceleration, modification or termination of any rights or obligations of any party thereto upon, or providing any party thereto any remedy (including rescission or liquidated damages) in the event of the consummation of the transactions contemplated by this Agreement;

(e) nondisclosure, noncompete or confidentiality agreements or agreements regarding ownership and rights with regard to work produced by employees, contractors or consultants;

(f) agreement under which the Company has advanced or loaned monies to any other Person or otherwise agreed to advance, loan or invest any funds (other than advances to the Company’s employees in the ordinary course of business under $10,000 with respect to each such employee);

(g) agreement or indenture relating to borrowed money or other Indebtedness, a guaranty of any obligation by the Company (for borrowed money or otherwise) or the mortgaging, pledging or otherwise granting of a Lien (including pursuant to any credit support or similar agreement) on any asset or group of assets of the Company, or any letter of credit arrangements or performance bond arrangements;

(h) guarantee of any obligation;

(i) power of attorney or other similar agreement or grant of agency;

(j) lease or agreement under which the Company is lessee of or holds or operates any property, real or personal, owned by any other party, except for any lease of real or personal property;

(k) lease or agreement under which the Company is lessor of or permits any third party to hold or operate any property, real or personal, owned or controlled by the Company;

(l) contract or group of related contracts with the same party or group of affiliated parties the performance of which involves consideration in excess of $100,000;

(m) assignment, license, indemnification or agreement with respect to any intangible property (including, without limitation, any Intellectual Property Rights (other than “off the shelf” licenses for third party software made available through regular commercial distribution channels on standard terms and conditions for aggregate license and maintenance fees of less than $25,000));

(n) warranty agreement with respect to its services rendered or its products sold or leased;

(o) agreement under which it has granted any Person any registration rights (including, without limitation, demand and piggyback registration rights);

(p) sales, distribution or franchise agreement;

(q) agreement with a term of more than one year which is not terminable by the Company upon less than 90 days’ notice without penalty;

(r) contract or agreement prohibiting it from freely engaging in any business or competing anywhere in the world or providing for exclusivity in any business line, geographic area or otherwise;

(s) contract or agreement containing a “most-favored nation”, “most favored pricing” or similar clause in favor of any Person;

(t) contract or agreement obligating the Company to pay any royalties, milestone payments, or other similar contingent payments to third parties with respect to the marketing, sale, distribution, manufacture, license of Company products or use of any Intellectual Property Rights; or

(u) any other agreement which is material to its operations or business, whether or not in the ordinary course of business.

Each contract or agreement of the character referred to in the respective clauses of Section 3.26(a) through 3.26(u) is referred to herein as a “Material Contract.”

Except as set forth on Section 3.26 of the Disclosure Schedule, the Company, and to the Company’s knowledge, each other party thereto have in all material respects performed all the actions required to be performed by them to date, have received no notice of default and are not in default under any Material Contract now in effect to which the Company is a party or by which it or its property may be bound. The Company has no present expectation or intention of not fully performing all its respective material obligations under each such Material Contact, and the Company has no knowledge of any material breach or anticipated breach by the other party to any Material Contract to which the Company is a party. The Company is in compliance with all of the terms and provisions of its Certificate of Incorporation and Bylaws.

3.27 OFAC. Neither the Company, and to the Company’s knowledge, no officer, employee or director of the Company, appears on the list of Specially Designated Nationals and Blocked Persons maintained by the U.S. Department of the Treasury’s Office of Foreign Assets Control. The purchase and sale of the Shares is not prohibited by Executive Order 13224, the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism (USA PATRIOT) Act of 2001, the Currency and Foreign Transactions Reporting Act of 1970, the United States Money Laundering Control Act of 1986, or the Trading with the Enemy Act of 1917 (TWEA).

3.28 FCPA. The Company has no officers, directors, or employees who are Foreign Officials as defined under the U.S. Foreign Corrupt Practices Act (“FCPA”). The Company has no officers, directors or employees who have Family Members (as defined under FCPA) who are Foreign Officials. The Company has not and will not, directly or indirectly, offer or pay, or authorize such offer or payment, any money or anything of value to improperly seek to influence any Foreign Official or foreign government entity decision-making or to gain a commercial or other advantage.

3.29 Disclosure. To the knowledge of the Company, neither this Agreement nor any other agreement, document, certificate or written statement furnished to the Purchasers or their special counsel by or on behalf of the Company in connection with the transactions contemplated hereby contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein or therein not misleading. There is no fact within the knowledge of the Company which has not been disclosed herein or in writing to the Purchasers and which could reasonably be expected to have a Material Adverse Effect.

ARTICLE 4

DEFINITIONS AND ACCOUNTING TERMS

4.1 Certain Defined Terms. As used in this Agreement, the following terms shall have the following meanings (such meanings to be equally applicable to both the singular and plural forms of the terms defined):

“Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person.

“Board of Directors” means the board of directors of the Company as constituted from time to time.

“Business Day” means any day other than (i) a Saturday or Sunday or (ii) a day on which banking institutions located in New York, New York are permitted or required by law, executive order or governmental decree to remain closed.

“Computer Programs” means (i) any and all computer programs (consisting of sets of statements or instructions to be used directly or indirectly in a computer in order to bring about a

certain result), and (ii) all associated data and compilations of data, regardless of their form or embodiment. “Computer Programs” shall include, without limitation, all source code, object code and natural language code therefor, all versions thereof, all screen displays and designs thereof, all component modules, all descriptions, flow-charts and other work product used to design, plan, organize and develop any of the foregoing, and all documentation, including without limitation user manuals and training materials, relating to any of the foregoing.

“Indebtedness” means all obligations, contingent and otherwise, which should, in accordance with generally accepted accounting principles, be classified upon the obligor’s balance sheet (or the notes thereto) as liabilities, but in any event including liabilities secured by any mortgage on property owned or acquired subject to such mortgage, whether or not the liability secured thereby shall have been assumed, and also including (i) all guaranties, endorsements and other contingent obligations, in respect of Indebtedness of others, whether or not the same are or should be so reflected in said balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business and (ii) the present value of any lease payments due under leases required to be capitalized in accordance with applicable Statements of Financial Accounting Standards, determined by discounting all such payments at the interest rate determined in accordance with applicable Statements of Financial Accounting Standards.

“Intellectual Property Rights” means all of the following: (i) patents, patent applications, patent disclosures and all related continuation, continuation-in-part, divisional, reissue, re-examination, utility, model, certificate of invention and design patents, patent applications, registrations and applications for registrations, (ii) trademarks, service marks, trade dress, logos, trade names, service names and corporate names and registrations and applications for registration thereof, (iii) copyrights and registrations and applications for registration thereof, (iv) mask works and registrations and applications for registration thereof, (v) trade secrets and confidential business information, whether patentable or non-patentable and whether or not reduced to practice, know-how, manufacturing and product processes and techniques, research and development information, copyrightable works, financial, marketing and business data, pricing and cost information, business and marketing plans and customer and supplier lists and information, (vi) Computer Programs, (vii) other proprietary rights relating to any of the foregoing (including without limitation associated goodwill and remedies against infringements thereof and rights of protection of an interest therein under the laws of all jurisdictions) and (viii) copies and tangible embodiments thereof.

“Key Employee” means and includes the President, Chief Executive Officer, any other executive-level employee and any employee or consultant who either alone or in concert with others develops, invents, programs or designs any Intellectual Property Rights of the Company.

“Lien” means, any mortgage, pledge, assessment, security interest, encumbrance, lien, lease, levy, claim or charge of any kind, including, without limitation, any conditional sale or other title retention agreement, any lease in the nature thereof and the filing of or agreement to give any financing statement under the Uniform Commercial Code of any jurisdiction and including any lien or charge arising by statute or other law.

“Person” means an individual, corporation, partnership, limited liability company, joint venture, trust, or unincorporated organization, or a government or any agency or political subdivision thereof or any other legal entity.

“Subsidiary” or “Subsidiaries” means any corporation or trust of which the Company and/or any of its other Subsidiaries directly or indirectly owns at the time outstanding shares of every class of such corporation or trust other than directors’ qualifying shares comprising at least fifty percent (50%) of the voting power of such corporation or trust.

4.2 Accounting Terms. All accounting terms not specifically defined herein shall be construed in accordance with GAAP as consistently applied, and all financial data submitted pursuant to this Agreement shall be prepared in accordance with such principles.

ARTICLE 5

MISCELLANEOUS

5.1 No Waiver; Cumulative Remedies. No failure or delay on the part of any party to this Agreement in exercising any right, power or remedy hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The remedies herein provided are cumulative and not exclusive of any remedies provided by law.

5.2 Amendments, Waivers and Consents. Except as otherwise provided in this Agreement, amendment or termination of this Agreement, and compliance with any covenant or provision set forth herein may be omitted or waived, if the Company shall obtain consent thereto in writing from the Purchaser or Purchasers holding a majority of the voting power of the Series D Preferred Shares then outstanding; provided that any such amendment, termination or waiver that occurs before the Closing shall require the written consent of the Company and the Purchasers obligated to purchase a majority of the Series D Preferred Shares to be issued to all Purchasers at the Closing. Any waiver or consent may be given subject to satisfaction of conditions stated therein and any waiver or consent shall be effective only in the specific instance and for the specific purpose for which given. Notwithstanding anything to the contrary contained herein, any amendment which (i) increases any Purchaser’s obligations hereunder, or (ii) grants to any one or more Purchasers any rights more favorable than any rights granted to all other Purchasers hereunder, must be approved by each Purchaser so as to be effective against such Purchaser.

5.3 Addresses for Notices. All notices, requests, consents and other communications under this Agreement shall be in writing and shall be deemed delivered (i) three (3) business days after being sent by registered or certified mail, return receipt requested, postage prepaid or (ii) one business day after being sent via a reputable nationwide overnight courier service guaranteeing next business day delivery, in each case to the intended recipient as set forth below:

if to any other holder of the Shares: at such holder’s address for notice as set forth in the register maintained by the Company, or, as to each of the foregoing, at the addresses set forth on

Schedule A hereto (and in the case of notice to TPG with a copy (which shall not constitute notice) to Xxxxxx LLP, Attn: Xxxxxx Xxxxx, 0000 Xxxxxxx Xxxxxx, Xxxxx 0000, Xxxxxxx, XX 00000-0000; or

if to the Company, at Collegium Pharmaceutical, Inc., 000 Xxxxxx Xxxxxx, Xxxxx 000, Xxxxxx, XX 00000, Attn: Chief Executive Officer, with a copy to Xxxxxx Xxxxxxxx LLP, 000 Xxxx Xxxxxx, Xxxxxx, Xxxxxxxxxxxxx 00000, Attention: Xxxxxx Xxxx, Esq.;

Any party may give any notice, request, consent or other communication under this Agreement using any other means (including, without limitation, personal delivery, messenger service, telecopy, first class mail or electronic mail), but no such notice, request, consent or other communication shall be deemed to have been duly given unless and until it is actually received by the party for whom it is intended. Any party may change the address to which notices, requests, consents or other communications hereunder are to be delivered by giving the other parties notice in the manner set forth in this Section 5.3.

5.4 Costs, Expenses and Taxes. Each party hereto shall bear its own expenses in connection with the transactions contemplated hereby; provided, however, the Company shall pay at the Closing the reasonable fees and expenses of Cooley and all other counsel to TPG in connection with the transactions contemplated hereby in an amount not to exceed $100,000, incurred in connection with their representation of their respective Purchaser clients in connection with the transactions contemplated hereby. The Company shall pay any and all stamp and other taxes payable or determined to be payable in connection with the execution and delivery of this Agreement, the issuance of the Preferred Shares and other instruments and documents to be delivered hereunder or thereunder, and agrees to save the Purchasers harmless from and against any and all liabilities with respect to or resulting from any delay in paying or omission to pay such taxes.

5.5 Binding Effect; Assignment. This Agreement shall be binding upon and inure to the benefit of the Company and the Purchasers and their respective heirs, successors and valid assigns, except that the Company shall not have the right to delegate any of its respective obligations hereunder or to assign its respective rights hereunder or any interest herein without the prior written consent of the holders of at least a majority in interest of the Shares.

5.6 Prior Agreements. This Agreement constitutes the entire agreement between the parties and supersedes any prior understandings or agreements concerning the purchase and sale of the Shares, including without limitation, the Summary of Terms for Series D Preferred Crossover Investment entered into with any of the Purchasers at any time before the date of this Agreement.

5.7 Severability. The provisions of this Agreement and the terms of the Series D Preferred Stock are severable and, in the event that any court of competent jurisdiction shall determine that any one or more of the provisions or part of a provision contained in this Agreement or the Preferred Stock shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part of a provision of this Agreement or the terms of the Series D Preferred Stock; but this Agreement and the terms of the Series D Preferred Stock shall be reformed and

construed as if such invalid or illegal or unenforceable provision, or part of a provision, had never been contained herein, and such provisions or part reformed so that it would be valid, legal and enforceable to the maximum extent possible.

5.8 Governing Law. This Agreement shall be construed and enforced in accordance with and governed by the laws of the Virginia Stock Corporation Act as to matters within the scope thereof, and as to all other matters shall be construed and enforced in accordance with and governed by the internal laws of the Commonwealth of Massachusetts, without regard to its principles of conflicts of laws.

5.9 Headings. Article, Section and subsection headings in this Agreement are included herein for convenience of reference only and shall not constitute a part of this Agreement for any other purpose.

5.10 Counterparts. This Agreement may be executed in any number of counterparts, all of which taken together, including facsimiles thereof, shall constitute one and the same instrument, and any of the parties hereto may execute this Agreement by signing any such counterpart.

5.11 Further Assurances. From and after the date of this Agreement, upon the request of any Purchaser or the Company, the Company and the Purchasers shall execute and deliver such instruments, documents and other writings as may be reasonably necessary or desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement and the Shares.

5.12 Indemnification. The Company shall, with respect to the representations, warranties and agreements made by it herein, indemnify, pay, defend and hold the Purchasers and each of the Purchasers’ officers, directors, employees and agents and their respective Affiliates (the “Indemnitees”) harmless against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever, including, without limitation, the reasonable fees and disbursements of counsel for such Indemnitees in connection with any investigative, administrative or judicial proceeding, whether or not such Indemnitees shall be designated a party thereto, which may be (i) imposed on such Indemnitee, (ii) incurred by such Indemnitee, or (iii) asserted against such Indemnitee by a third party, in each case, based upon, arising out of or otherwise in respect of any breach by the Company of any representation or warranty of the Company contained in this Agreement.

5.13 Survival. All representations, warranties, covenants and agreements contained herein or made in writing by any party in connection herewith shall survive the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby, regardless of any investigation made by any Purchaser or on its behalf.

5.14 Attorneys’ Fees. If any action at law or in equity (including, arbitration) is necessary to enforce or interpret the terms of any of the Transaction Agreements, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled.

5.15 Delivery by Facsimile or PDF. This Agreement and any agreement or instrument entered into in connection with this Agreement, and any amendments hereto or thereto, to the extent signed and delivered by means of a facsimile machine or portable document format (pdf) sent by electronic mail, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party hereto or to any such agreement or instrument, each other party hereto or thereto shall re-execute original forms thereof and deliver them to all other parties. No party hereto or to any such agreement or instrument shall raise the use of a facsimile machine or emailed pdf to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of a facsimile machine or emailed pdf as a defense to the formation of a contract and each such party forever waives any such defense.

5.16 . The Company will consult with the other and obtain the consent of TPG (which consent shall not be unreasonably withheld, conditioned or delayed) before issuing any press releases or any public statements with respect to this Agreement and the transactions contemplated by this Agreement, except as may be required by law or stock exchange rules, in which case the Company shall use reasonable efforts to provide TPG a reasonable opportunity to comment on such press release or public announcement in advance of the time of disclosure of such publication or such other communication.

5.17 Public Acknowledgement. Each party to this Agreement acknowledges that Cooley, counsel to TPG, has in the past performed services for, or represented, or currently represents, or may in the future represent: (a) the Company with regard to patent prosecution and other intellectual property matters unrelated to the transactions contemplated by this Agreement (the “Financing”), and /or (b) other Purchasers or their affiliates in matters of a similar nature to the Financing, including prior rounds of financing of the Company. The applicable rules of professional conduct require that Cooley inform the parties hereunder of this representation and obtain their consent. Cooley has served as counsel only to TPG and has negotiated the terms of the Financing, and conducted diligence on the Company in connection with the financing, solely on behalf of TPG and not on behalf of either the Company or any other Purchasers. The Company and each Purchaser hereby (a) acknowledge that they have had an opportunity to ask for and have obtained information relevant to such representation, including disclosure of the reasonably foreseeable adverse consequences of such representation; (b) acknowledge that with respect to the Financing and all related diligence and matters, Cooley has represented solely TPG and not the Company or any other Purchaser or any stockholder, director or employee of the Company or any other Purchaser; and (c) gives its informed consent to Xxxxxx’x representation of TPG in the Financing and all related diligence and matters.

[Remainder of this Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as an instrument under seal as of the date first above written.

THE COMPANY:

COLLEGIUM PHARMACEUTICAL, INC.

By:	/s/ Xxxxxxx Xxxxxxxxx
Name:	Xxxxxxx Xxxxxxxxx
Title:	President and Chief Executive Officer

[Signature page continues]

[Signature Page to Series D Preferred Stock Purchase Agreement]

PURCHASERS:

TPG BIOTECHNOLOGY PARTNERS IV, L.P.

By:	TPG Biotechnology GenPar IV, L.P.,
	Its general partner

By:	TPG Biotechnology GenPar IV Advisors, LLC,
	Its general partner

By:		/s/ Xxxxxx Xxxxx
Name:		Xxxxxx Xxxxx
Title:		Vice President

[Signature page continues]

[Signature Page to Series D Convertible Preferred Stock Purchase Agreement]

PURCHASERS (Cont.):

ADAGE CAPITAL PARTNERS, LP

By:		Adage Capital Partners, GP, LLC, it’s General Partner
By:		Adage Capital Advisors, LLC it’s Managing Member

By:	/s/ Xxx Xxxxx
Name:	Xxx Xxxxx
Title:	Chief Operating Officer

[Signature page continues]

[Signature Page to Series D Preferred Stock Purchase Agreement]

PURCHASERS (Cont.):

EcoR1 Capital Fund, L.P.
By:	/s/ Xxxx Xxxxxxxx
Name:	Xxxx Xxxxxxxx
Title:	Managing Director, EcoR1 Capital, LLC

EcoR1 Capital Fund Qualified, L.P.
By:	/s/ Xxxx Xxxxxxxx
Name:	Xxxx Xxxxxxxx
Title:	Managing Director, EcoR1 Capital, LLC

[Signature page continues]

[Signature Page to Series D Preferred Stock Purchase Agreement]

PURCHASERS (Cont.):


RA CAPITAL HEALTHCARE FUND, LP

By:	/s/ Xxxxx Xxxxxxxxxx
Name:	Xxxxx Xxxxxxxxxx
Title:	Manager

[Signature page continues]

[Signature Page to Series D Preferred Stock Purchase Agreement]

PURCHASERS (Cont.):


ROCK SPRINGS CAPITAL MASTER FUND LP

By: Rock Springs GP LLC
Its: General Partner

By:	/s/ Xxxxxx XxXxxxx
Name:	Xxxxxx XxXxxxx
Title:	Managing Director

[Signature page continues]

[Signature Page to Series D Preferred Stock Purchase Agreement]

PURCHASERS (Cont.):

EVENTIDE HEALTHCARE AND LIFE SCIENCES FUND


By:	/s/ Xxxxxxxx Xxxxxx
Name:	Xxxxxxxx Xxxxxx
Title:	Secretary, Mutual Fund Services Trust

EVENTIDE GILEAD FUND


By:	/s/ Xxxxxxxx Xxxxxx
Name:	Xxxxxxxx Xxxxxx
Title:	Secretary, Mutual Fund Services Trust

[Signature page continues]

[Signature Page to Series D Preferred Stock Purchase Agreement]

PURCHASERS (Cont.):

APERTURE VENTURE PARTNERS III, L.P.

By: Aperture Ventures III Management, LLC, its General Partner

By:	/s/ Xxxx Xxxxxxx
Name:	Xxxx Xxxxxxx
Title:	Managing Member

[Signature page continues]

[Signature Page to Series D Convertible Preferred Stock Purchase Agreement]

PURCHASERS (Cont.):

LONGITUDE VENTURE PARTNERS, L.P.
A Delaware Limited Partnership

By: Longitude Capital Partners, LLC
Its General Partner

By:		/s/ Xxxxxxx Xxxxxxx
Name:		Xxxxxxx Xxxxxxx
Title:		Managing Member

LONGITUDE CAPITAL ASSOCIATES, L.P.
A Delaware Limited Partnership

By: Longitude Capital Partners, LLC
Its General Partner

By:	/s/ Xxxxxxx Xxxxxxx
Name:	Xxxxxxx Xxxxxxx
Title:	Managing Member

[Signature page continues]

[Signature Page to Series D Preferred Stock Purchase Agreement]

PURCHASERS (Cont.):

SKYLINE VENTURE PARTNERS V, L.P.

By:		Skyline Venture Management V, LLC
Its:		General Partner


By:	/s/ Xxxx X. Xxxxxx
Name:	Xxxx X. Xxxxxx
Title:	Managing Director

XXXXXXX HEALTHCARE VI, LP

By FHM VI, LP, its general partner
By FHM VI, LLC, its general partner

By:	/s/ Xxxxxxx Xxxxx
Name:	Xxxxxxx Xxxxx
Title:	Manager

[Signature page continues]

[Signature Page to Series D Convertible Preferred Stock Purchase Agreement]

PURCHASERS (Cont.):

BOSTON MILLENNIA PARTNERS II LIMITED PARTNERSHIP
By: Xxxx Partners II Limited Partnership

By:	/s/ Xxxxxx X. Xxxxxx
Name:	Xxxxxx X. Xxxxxx
Title:	General Partner

BOSTON MILLENNIA PARTNERS II-A LIMITED PARTNERSHIP
By: Xxxx Partners II Limited Partnership

By:	/s/ Xxxxxx X. Xxxxxx
Name:	Xxxxxx X. Xxxxxx
Title:	General Partner

BOSTON MILLENNIA PARTNERS GMBH & CO. KG
By: Boston Millenia Verwaltungs GmbH

By:	/s/ Xxxxxx X. Xxxxxx
Name:	Xxxxxx X. Xxxxxx
Title:	Managing Director

BOSTON MILLENNIA ASSOCIATES II PARTNERSHIP

By:	/s/ Xxxxxx X. Xxxxxx
Name:	Xxxxxx X. Xxxxxx
Title:	General Partner

STRATEGIC ADVISORS FUND LIMITED PARTNERSHIP

By: Xxxx Partners II Limited Partnership,
Its General Partner

By:	/s/ Xxxxxx X. Xxxxxx
Name:	Xxxxxx X. Xxxxxx
Title:	General Partner

[Signature page continues]

[Signature Page to Series D Convertible Preferred Stock Purchase Agreement]

SCHEDULE A

Purchasers

Name of Purchaser	Aggregate Purchase Price Paid in Cash		Aggregate Purchase Price Paid with Note	No. of Series D Preferred Shares Purchased
TPG Biotechnology Partners IV, L.P. 000 Xxxxxxxxxx Xxxxxx, Xxxxx 0000 Xxx Xxxxxxxxx, XX 00000 Fax: (000) 000-0000	$	9,999,999.60	n/a	8,333,333

Adage Capital Partners, LP 000 Xxxxxxxxx Xx., 00xx Xxxxx Xxxxxx, XX 00000 Attn: Xxx Xxxxx, COO	$	3,999,999.60	n/a	3,333,333

EcoR1 Capital Fund, L.P. c/o EcoR1 Capital, LLC 000 Xxxxxxxx Xxxxxx Xxx Xxxxxxxxx, XX 00000	$	743,000.40	n/a	611,667

EcoR1 Capital Fund Qualified , L.P. c/o EcoR1 Capital, LLC 000 Xxxxxxxx Xxxxxx Xxx Xxxxxxxxx, XX 00000	$	1,266,000	n/a	1,055,000

RA Capital Healthcare Fund, LP c/o RA Capital Management, LLC 00 Xxxx Xxxxx, Xxxxx 0000 Xxxxxx, XX 00000	$	6,999,999.60	n/a	5,833,333

Rock Springs Capital Master Fund LP 000 Xxxxx Xxxxxx Xxxxxx Xxxxxxxxx, XX 00000 Attn: Chief Financial Officer	$	3,999,999.60	n/a	3,333,333

Eventide Healthcare and Life Sciences Fund c/o Eventide Asset Management, LLC 00 Xxxxx Xxxxxx Xxxxx 000 Xxxxxx, XX 00000 Attn: BJ Cheriakalath, COO	$	2,000,000.40	n/a	1,666,667

A-1

Eventide Gilead Fund c/o Eventide Asset Management, LLC 00 Xxxxx Xxxxxx, Xxxxx 000 Xxxxxx, XX 00000 Attn: BJ Cheriakalath, COO	$	999,999.60	n/a		833,333

Aperture Venture Partners III, L.P. c/o Aperture Venture Partners, LLC 000 Xxxxxxx Xxxxxx, 00xx Xxxxx Xxx Xxxx, XX 00000 Attn: Xxxx Xxxxxxx	$	1,500,000	n/a		1,250,000

Longitude Venture Partners, L.P. 000 Xxxxxxxxx Xxxx Xxxxxxxxx, XX 00000 Fax:	$	4,263,848.57	$	1,790,608.63	5,045,381

Longitude Capital Associates, L.P. 000 Xxxxxxxxx Xxxx Xxxxxxxxx, XX 00000 Fax:	$	85,463.31	$	35,890.29	101,128

Skyline Venture Partners V, L.P. 000 Xxxxxxxxxx Xxxxxx Xxxxx 000 Xxxx Xxxx, XX 00000 Fax: 000-000-0000	$	5,563,660.74	$	1,494,408.06	5,881,724

Xxxxxxx Healthcare VI, LP 000 Xxxxxxxx Xxx. Xxxxx 000 Xxxx Xxxx, XX 00000 Fax: (000) 000-0000	$	3,487,029.13	$	924,264.47	3,676,078

Boston Millennia Partners II Limited Partnership 00 Xxxxx Xxxxx, Xxxxx 000 Xxxxxx, XX 00000 Fax: (000) 000-0000	$	83,031.92	$	626,750.08	591,485

Boston Millennia Partners II-A Limited Partnership 00 Xxxxx Xxxxx, Xxxxx 000 Xxxxxx, XX 00000 Fax: (000) 000-0000	$	3,977.93	$	30,022.87	28,334

Boston Millennia Partners GmbH & Co. KG 00 Xxxxx Xxxxx, Xxxxx 000 Xxxxxx, XX 00000	$	11,823.81	$	89,249.79	84,228

A-2

Fax: (000) 000-0000

Strategic Advisors Fund Limited Partnership 00 Xxxxx Xxxxx, Xxxxx 000 Xxxxxx, XX 00000 Fax: (000) 000-0000	$	746.08	$	5,635.52	5,318

Boston Millennia Associates II Partnership 00 Xxxxx Xxxxx, Xxxxx 000 Xxxxxx, XX 00000 Fax: (000) 000-0000	$	420.11	$	3,170.29	2,992

Totals:	$	45,000,0000.40	$	5,000,000.00	41,666,667

A-3

SCHEDULE B

Disclosure Schedule

B-1

Exhibit 1.1

Restated Certificate

Exhibit 2.1(c)(ii)

Opinion of Xxxxxx Xxxxxxxx

Exhibit 2.1(c)(v)

Seventh Amended and Restated Stockholders Agreement

Exhibit 2.1(c)(vii)

Eighth Amended and Restated Investor Rights Agreement

Document Metadata

Table of Contents

COLLEGIUM PHARMACEUTICAL, INC. Series D Convertible Preferred Stock Purchase Agreement Dated as of March 6, 2015

Document Metadata